Z-Pak and the Risk of Cardiovascular Death

Zithromax

Hundreds of thousands of people across the country have taken or are currently using the antibiotic Zithromax, a drug developed by Pfizer, Inc., and most commonly marketed as Z-Pak until the company’s patent expired and generic versions of the drug became available to the public. According to research recently published in the New England Journal of Medicine, all of these patients were or are currently exposed to an elevated risk of cardiac death as a direct result of using Z-Pak.

These disturbing findings were the result of an extensive study of the short-term effects of a variety of antibiotic drugs over a five day period, and examined the increased risk of cardiovascular death associated with a course of treatment. With the new information that has been brought to life, it is possible that Pfizer, Inc., has been negligent in its duty to inform consumers of the potential health risks associated with the use of their product and may be liable for the losses suffered by a large number of patients who suffered cardiac death or other negative health effects during the course of treatment with Z-Pak.  As in the case of the Granuflo lawsuit, this fact has led to potential litigation against Pfizer.

Statistics and Numbers

The clinical trial revealing the increased risk of fatal cardiovascular events while taking Z-Pak was run concurrently with trials of amoxicillin, ciprofloxacin, levofloxacin, and a control group which took no antibiotics, and the following data was compiled:

  • Patients taking amoxicillin experienced no increased risk of cardiovascular death
  • Patients taking Z-Pak experienced an estimated 47 additional deaths per 1 million courses
  • Patients already at high risk of heart disease experienced an estimated 245 additional deaths per 1 million courses due to cardiovascular complications
  • Patients experienced a small but clear absolute increase in risk of cardiovascular death while taking Z-Pak.

Pfizer, Inc., the maker of the drug which generated $453 million last year, has commented that they are reviewing the study within the context of their own information compiled on the drug’s effects, but has yet made no move to issue a recall. If someone you love has suffered cardiovascular death or other complications while taking a course of Z-Pak, you may be entitled to compensation for the losses you have experienced.

Leave a Reply

Your email address will not be published. Required fields are marked *